CD8A and neoplasm: Engagement of innate and adaptive immune checkpoint molecules via CD47 × PD‐L1 BisAb treatment resulted in robust CD8+ T cell responses, including the induction of tumor‐resident CD8+ T cells that exhibited functionally superior anti‐tumor immunity.